(269 days)
No
The document describes a software algorithm for calculating respiration rate based on oximetry data, but it does not mention the use of AI, ML, or related terms like neural networks or deep learning. The description focuses on a "modification to the principles of operation of the RR software algorithm," suggesting a rule-based or traditional signal processing approach rather than a learning-based one.
No
The device is a monitoring system that measures physiological parameters (SpO2, pulse rate, respiration rate) but does not provide therapy or treatment.
No
The device is a continuous non-invasive monitor of physiological parameters (SpO2, pulse rate, respiration rate) which provide data for medical professionals but does not provide a diagnosis itself.
No
The device is described as a "Nellcor™ Bedside Respiratory Patient Monitoring System (oximeter)" which contains the software. The description explicitly states it is an "oximeter" and mentions the use of "compatible Nellcor OxiMax oxygen transducers (sensors)" to acquire data, indicating it is a hardware device with integrated software.
Based on the provided text, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Nellcor™ Bedside Respiratory Patient Monitoring System is a non-invasive monitor that measures physiological parameters (SpO2, pulse rate, respiration rate) directly from the patient's body using sensors. It does not analyze samples taken from the body.
Therefore, this device falls under the category of a non-invasive patient monitoring system, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The Nellcor™ Bedside Respiratory Patient Monitoring System is a portable pulse oximeter intended for prescription use only as a continuous non-invasive monitor of arterial oxygen saturation (SpO2) and pulse rate of adult, pediatric, and neonatal patients during both motion conditions, and for patients who are well or poorly perfused. The monitoring system is intended for use in hospital-type facilties, and during intra-hospital transport. The OxiMax SPD™ Alert (SPD) feature is intended only for facility-use care of adults to detect patterns of desaturation indicative of repetitive reductions in airflow through the upper airway and into the lungs.
The Nellcor™ Respiration Rate parameter, when used in conjunction with the Nellcor™ Bedside Respiratory Patient Monitoring System and Nellcor™ Adult Respiratory Sensor, is intended for the continuous, non-invasive monitoring of respiration rate in adult patients in hospitals and hospital-type facilities.
Product codes
DQA, BZQ
Device Description
The subject device is the Nellcor™ Bedside Respiratory Patient Monitoring System (oximeter) which contains the Nellcor™ Respiration Rate Parameter (RR Version 2.0 Application device). The oximeter is designed for continuous, non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate, and respiratory rate by use of one of compatible Nellcor OxiMax oxygen transducers (sensors). The oximeter displays digital values of SpO2 and pulse and respiratory rate. The oximeter device features the same technological characteristics as the predicate, which is the exact same system featuring a system software upgrade.
The oximeter features the optional Nellcor™ Respiration Rate (RR) Software Application for use on the finished oximeter device. Covidien is submitting this traditional 510(k) submission as the result of a design change to the RR software device residing on the oximeter. The design change to the RR Software Application involves a modification to the principles of operation of the RR software algorithm.
The RR software application is intended for continuous non-invasive monitoring of respiration rate in adult patients, and it is calculated by an RR algorithm residing on the monitor which derives patient respiratory rate in breaths per minute based upon oximetry photoplethysmography data that is received from the oximetry sensor on the patient. The software parameter was cleared by the FDA through traditional 510(k) premarket notification (K111933) as the Nellcor Respiration Rate Software, Version 1.0 on March 15, 2012. Version 2.0 (V2.0) of the Respiration Rate (RR) software is an upgraded design of the original cleared software.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult, pediatric, and neonatal patients (for SpO2 and pulse rate monitoring); adult patients (for respiration rate monitoring).
Intended User / Care Setting
prescription use only; hospital-type facilities, and during intra-hospital transport.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Non-clinical performance data summary:
Testing incorporating simulated motion performed to validate pulse rate accuracy across the operating range of 20 to 250 beats per minute, and testing incorporating simulated motion performed to validate respiration rate accuracy across the operating range of 4 to 40 breaths per minute.
The simulated motion data used to assess respiration rate performance was collected from monitored patients on the general care floor which represents the intended populations and includes extreme boundaries of patient characteristics and artifact. Specifically, this simulation assesses respiration rate accuracy in the presence of motion artifact under conditions of low pulse rate (5th percentile) and low perfusion (5th percentile) and low respiratory variations for all of frequency, amplitude and baseline modulations (all 10th percentile).
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical performance data summary:
The appropriate safety, environmental, performance and functional testing was conducted to ensure that the specifications of the Nellcor Respiration Rate Software and Nellcor™ Adult Respiratory Sensor were met.
The performance testing section of this submission includes verification and validation reports for pulse oximetry performance in accordance with FDA Guidance document: "Pulse Oximeters - Premarket Notification Submissions [510(k)s] Guidance for Industry and Food and Drug Administration Staff". Nonclinical testing in this submission includes, but is not limited to. ISO 80601-2-61:2011 and IEC 60601-1:2005 test reports, Oximetry performance verification, Human Factors Summative Usability validation, testing incorporating simulated motion performed to validate pulse rate accuracy across the operating range of 20 to 250 beats per minute, and testing incorporating simulated motion performed to validate respiration rate accuracy across the operating range of 4 to 40 breaths per minute.
The results of this testing demonstrate that the Nellcor™ Bedside Respiratory Patient Monitoring System has a respiration rate measurement range of 4 to 40 breaths per minute with an accuracy of +1 breath per minute, and is substantially equivalent to the predicate device with respect to Respiration Rate (for adults).
Clinical Summary:
Clinical validation studies on healthy adult volunteers and on subjects from the hospital general care floor were conducted to assess the accuracy of the Respiration Rate Software algorithm. The studies demonstrated the accuracy of the Respiration Rate Software algorithm was as good as the predicate. The studies demonstrated the Respiration Rate Software algorithm calculates respiration rate within a stated accuracy of +1 breath per minute over a range of 4-32 breaths per minute and is shown to be substantially equivalent to the predicate device.
No device related adverse events were observed during the clinical studies.
Conclusion:
The information provided in this 510(k) demonstrates the Nellcor™ Bedside Respiratory Patient Monitoring System is substantially equivalent to the predicate devices with respect to performance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Respiration rate measurement range: 4-40 breaths/minute.
Accuracy: +1 breath/minute.
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.2700 Oximeter.
(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of three human profiles facing right, stacked on top of each other. Above the profiles are three curved lines, resembling flowing hair or abstract shapes. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the emblem.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 5, 2015
Covidien Jamie Thomas Senior Regulatory Affairs Specialist 6135 Gunbarrel Ave. Boulder, CO 80301
Re: K141518
Trade/Device Name: Nellcor™ Bedside Respiratory Patient Monitoring System Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: DQA, BZQ Dated: January 30, 2015 Received: February 2, 2015
Dear Ms. Thomas,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Tejashri Purohit-Sheth, M.D.
Tejashri Purohit-Sheth, M.D. Clinical Deputy Director DAGRID/ODE/CDRH FOR
Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K141518
Device Name
Nellcor™ Bedside Respiratory Patient Monitoring System
Indications for Use (Describe)
The Nellcor™ Bedside Respiratory Patient Monitoring System is a portable pulse oximeter intended for prescription use only as a continuous non-invasive monitor of arterial oxygen saturation (SpO2) and pulse rate of adult, pediatric, and neonatal patients during both motion conditions, and for patients who are well or poorly perfused. The monitoring system is intended for use in hospital-type facilties, and during intra-hospital transport. The OxiMax SPD™ Alert (SPD) feature is intended only for facility-use care of adults to detect patterns of desaturation indicative of repetitive reductions in airflow through the upper airway and into the lungs.
The Nellcor™ Respiration Rate parameter, when used in conjunction with the Nellcor™ Bedside Respiratory Patient Monitoring System and Nellcor™ Adult Respiratory Sensor, is intended for the continuous, non-invasive monitoring of respiration rate in adult patients in hospitals and hospital-type facilities.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807.92, provided is the 510(k) summary for the Nellcor™ Bedside Respiratory Patient Monitoring System.
SUBMITTER INFORMATION:
| Submitted By: | Covidien
6135 Gunbarrel Avenue
Boulder, CO 80301 |
|----------------------|--------------------------------------------------------|
| Contact: | Jamie Thomas
Sr. Regulatory Affairs Specialist |
| Phone: | 303-305-2315 |
| Fax: | 303-305-2212 |
| Date of Preparation: | June 6, 2014 |
Device Name:
| Trade Name(s): | Nellcor ™ Bedside Respiratory Patient Monitoring System |
|---|---|
| Common/Usual Name: | Pulse Oximeter |
| Classification Names: | Class II, Anesthesiology |
| CFR Reference: | 21 CFR 870.2700 |
| Product Code: | DQA, BZQ |
PREDICATE DEVICES:
| Covidien Nellcor™ Bedside
Respiratory Patient Monitoring
| System | K121806 |
|---|---|
| Covidien Nellcor™ Bedside | |
| Respiratory Patient Monitoring | |
| System | K123581 |
| Covidien Nellcor™ Bedside | |
| Respiratory Patient Monitoring | |
| System | K130320 |
DEVICE DESCRIPTION:
The subject device is the Nellcor™ Bedside Respiratory Patient Monitoring System (oximeter) which contains the Nellcor™ Respiration Rate Parameter (RR Version 2.0 Application device). The oximeter is designed for continuous, non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate, and respiratory rate by use of one of compatible Nellcor OxiMax oxygen transducers (sensors). The oximeter displays digital values of SpO2 and pulse and respiratory rate. The oximeter device features the same technological characteristics as the predicate, which is the exact same system featuring a system software upgrade.
4
The oximeter features the optional Nellcor™ Respiration Rate (RR) Software Application for use on the finished oximeter device. Covidien is submitting this traditional 510(k) submission as the result of a design change to the RR software device residing on the oximeter. The design change to the RR Software Application involves a modification to the principles of operation of the RR software algorithm.
The RR software application is intended for continuous non-invasive monitoring of respiration rate in adult patients, and it is calculated by an RR algorithm residing on the monitor which derives patient respiratory rate in breaths per minute based upon oximetry photoplethysmography data that is received from the oximetry sensor on the patient. The software parameter was cleared by the FDA through traditional 510(k) premarket notification (K111933) as the Nellcor Respiration Rate Software, Version 1.0 on March 15, 2012. Version 2.0 (V2.0) of the Respiration Rate (RR) software is an upgraded design of the original cleared software.
INDICATIONS FOR USE:
The Nellcor™ Bedside Respiratory Patient Monitoring System is a portable pulse oximeter intended for prescription use only as a continuous non-invasive monitor of arterial oxygen saturation (SpO2) and pulse rate of adult, pediatric, and neonatal patients during both motion conditions, and for patients who are well or poorly perfused. The monitoring system is intended for use in hospitals, hospitaltype facilities, and during intra-hosport. The OxiMax SPD™ Alert (SPD) feature is intended only for facility-use care of adults to detect patterns of desaturation indicative of repetitive reductions in airflow through the upper airway and into the lungs.
The Nellcor™ Respiration Rate parameter, when used in conjunction with the Nellcor™ Bedside Respiratory Patient Monitoring System and Nellcor™ Adult Respiratory Sensor, is intended for the continuous, non-invasive monitoring of respiration rate in hospitals and hospitals and hospital type facilities.
TECHNOLOGICAL CHARACTERISTICS SUMMARY & SUBSTANTIAL EQUIVALENCE STATEMENT:
The subject device, is the Nellcor™ Bedside Respiratory Patient Monitoring System (oximeter) which contains the Nellcor™ Respiration Rate Software Version 2.0 Application (RR software device), has the same intended use (Adults), general design (continuous, non-invasive indication of respiration rate) and fundamental scientific technology (indicator of central ventilatory drive) as the predicate device Nellcor™ Bedside Respiratory Patient Monitoring System K130320, K123581 and K121806.
The Respiration Rate Software uses photoplethysmography to calculate respiration rate, both of which are indicators of central ventilator drive. The respiration rate measurement range for the Respiration Rate Software is 4-40 breaths/minute, and is indicated for adults only. Both the subject and predicate devices have an accuracy of +1 breaths/minute for the adult population.
PERFORMANCE DATA SUMMARY:
Non-clinical performance data summary
The appropriate safety, environmental, performance and functional testing was conducted to ensure that the specifications of the Nellcor Respiration Rate Software and Nellcor™ Adult Respiratory Sensor were met.
The performance testing section of this submission includes verification and validation reports for pulse oximetry performance in accordance with FDA Guidance document: "Pulse Oximeters - Premarket Notification Submissions [510(k)s] Guidance for Industry and Food and Drug Administration Staff". Nonclinical testing in this submission includes, but is not limited to. ISO 80601-2-61:2011 and IEC 60601-1:2005 test reports, Oximetry performance verification, Human Factors Summative Usability validation, testing incorporating simulated motion performed to validate pulse rate accuracy across the operating
5
range of 20 to 250 beats per minute, and testing incorporating simulated motion performed to validate respiration rate accuracy across the operating range of 4 to 40 breaths per minute.
The simulated motion data used to assess respiration rate performance was collected from monitored patients on the general care floor which represents the intended populations and includes extreme boundaries of patient characteristics and artifact. Specifically, this simulation assesses respiration rate accuracy in the presence of motion artifact under conditions of low pulse rate (5th percentile) and low perfusion (5th percentile) and low respiratory variations for all of frequency, amplitude and baseline modulations (all 10th percentile) and validates the respiration rate accuracy across the range of 4 to 40 breaths per minute.
The results of this testing demonstrate that the Nellcor™ Bedside Respiratory Patient Monitoring System has a respiration rate measurement range of 4 to 40 breaths per minute with an accuracy of +1 breath per minute, and is substantially equivalent to the predicate device with respect to Respiration Rate (for adults).
Clinical Summary
Clinical validation studies on healthy adult volunteers and on subjects from the hospital general care floor were conducted to assess the accuracy of the Respiration Rate Software algorithm. The studies demonstrated the accuracy of the Respiration Rate Software algorithm was as good as the predicate. The studies demonstrated the Respiration Rate Software algorithm calculates respiration rate within a stated accuracy of +1 breath per minute over a range of 4-32 breaths per minute and is shown to be substantially equivalent to the predicate device.
No device related adverse events were observed during the clinical studies.
Conclusions
The information provided in this 510(k) demonstrates the Nellcor™ Bedside Respiratory Patient Monitoring System is substantially equivalent to the predicate devices with respect to performance.